1:40 PM
 | 
Feb 12, 2018
 |  BC Extra  |  Company News

Poxel finds U.S., European partner for imeglimin

Poxel S.A. (Euronext:POXEL) added €0.65 (10%) to €6.87 on Monday after granting Roivant Sciences GmbH (Basel, Switzerland) rights to late-stage Type II diabetes candidate imeglimin (PXL008). Poxel will receive an upfront payment of $35 million and is eligible for up to $600 million in development, regulatory and sales-based milestones, plus double-digit royalties. Concurrently,...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >